
AI Can Boost Accuracy When Classifying HER2-Low, HER2-Ultralow Breast Cancers, Findings Show
In recent years, practice changing data have shown that trastuzumab deruxtecan (Enhertu) can improve survival among patients who express the protein human epidermal growth factor receptor 2 (HER2) below the traditional level deemed HER2-positive. But this …